GENECURE: GENomic stratEgies for treatment and prevention of Cardiovascular death in Uraemia and end-stage REnal disease

In renal failure cardiovascular (CV) risk is greatly enhanced, posing a large burden on both patient and society. Elucidation of its genetic basis is important to allow innovative prevention strategies in these patients by: a) early identification of subjects at risk; b) better allocation of available prevention and treatment modalities and c) identification of novel pathways of organ damage as new targets for intervention. The aims of GENECURE were pursued by a coherent set of studies and initiatives that 1) linked existing initiatives into a joint infrastructure for collaborative genetic studies in renal populations (by the development of the Renal Biobank Catalogue and the Renal DataSHaPER),  and 2) studied genes relevant to accelerated CV damage in end-stage renal disease, in terms of natural course and response to intervention, with emphasis on identification of targets for primary and secondary prevention. Furthermore, candidate genes from established pathophysiological pathways were studied, and novel candidates identified from hypothesis free studies in rodent models and human tissue. In addition, a statistical risk model on impact of genetic and environmental factors over time was developed for clinical use in risk stratification and decision making (to be tested in future prospective studies) and for scientific use for identification of research targets likely to have the largest clinical impact. The GENECURE project was led by Prof. dr G.J. Navis. The project ended in July 2010.